Sugi Predict

Sugi Predict / Compounds / SCHEMBL1702340

SCHEMBL1702340

SCHEMBL1702340

NCCC[C@@H](N)C(=O)OC(=O)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ PAM P19021 1/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ LTA4H P09960 1/20 0.43
▸ SLC7A5 Q01650 2/20 0.40
▸ ALPI P09923 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ XIAP P98170 1/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ DPP9 Q86TI2 1/20 0.40
▸ DPP7 Q9UHL4 1/20 0.40
▸ GSR P00390 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ GRIK1 P39086 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28231845 0.96 MMP2 (0.50) ALDH1A1MAPK1L3MBTL1PAMMMP2
SCHEMBL17458666 0.85 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1PAMTSHR
SCHEMBL1832634 0.85 TDP1 (0.46) MAPK1MMP2GRIK1
SCHEMBL1537320 0.84 ALPI (0.53) MMP2LTA4HSLC7A5ALPIPKM
SCHEMBL402494 0.82 L3MBTL1 (0.46) ALDH1A1MAPK1L3MBTL1PAMTSHR
SCHEMBL8740769 0.81 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1PAMTSHR
SCHEMBL15532005 0.81 SLC7A5 (0.58) ALDH1A1MAPK1L3MBTL1PAMTSHR
SCHEMBL3340704 0.81 L3MBTL1 (0.45) ALDH1A1MAPK1L3MBTL1PAMTSHR
SCHEMBL7391550 0.81 LTA4H (0.48) ALDH1A1MAPK1L3MBTL1MMP2LTA4H
SCHEMBL17164597 0.80 DPP8 (0.40) ALDH1A1MAPK1L3MBTL1PAMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516015-B2 L-ornithine phenyl acetate and methods of making thereof AMALIVE LIMITED (GB) 2026-01-06 — — US claimed
US-12396675-B2 Methods of assessing hepatic encephalopathy AMALIVE LIMITED (GB) 2025-08-26 — — US claimed
US-20250170157-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY LEXICON PHARMACEUTICALS, INC. 2025-05-29 — — US claimed
WO-2025101731-A1 SGLT1 INHIBITORS FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY LEXICON PHARMACEUTICALS, INC. (US) 2025-05-15 — — WO claimed
WO-2024261477-A1 COMBINATION OF TLR4 ANTAGONIST, ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE YAQRIT LIMITED (GB) 2024-12-26 — — WO claimed
WO-2024194181-A1 NH3 SCAVENGER FOR USE IN THE TREATMENT OF MOBILITY DISABILITY IN A POST-STROKE PATIENT Merz Therapeutics GmbH (DE) 2024-09-26 — — WO claimed
WO-2024149252-A1 MAGNESIUM PHOSPHATE SUBSTANCE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF 上海石趣医药科技有限公司 2024-07-18 — — WO claimed
EP-4205735-A1 FORMULATIONS OF L-ORNITHINE PHENYLACETATE Ocera Therapeutics, Inc. (US) 2023-07-05 — — EP claimed
US-20230201148-A1 USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA MALLINCKRODT LLC 2023-06-29 — — US claimed
CN-115916179-A Use of ornithine phenylacetate for treating hyperammonemia 欧塞拉治疗有限公司 2023-04-04 — — CN claimed
US-20170056416-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY UMECRINE COGNITION AB (SE) 2017-03-02 — — US claimed
WO-2017031131-A1 TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE OCERA THERAPEUTICS, INC. (US) 2017-02-23 — — WO claimed
EP-3099306-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY Umecrine Cognition AB (SE) 2016-12-07 — — EP claimed
US-20160339040-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY UMECRINE COGNITION AB (SE) 2016-11-24 — — US claimed
US-20160338982-A1 FORMULATIONS OF L-ORNITHINE PHENYLACETATE OCERA THERAPEUTICS LLC 2016-11-24 — — US claimed
CN-106163528-A Steroids for the treatment of hepatic encephalopathy 梅克芳识别有限公司 2016-11-23 — — CN claimed
WO-2016172112-A1 FORMULATIONS OF L-ORNITHINE PHENYLACETATE OCERA THERAPEUTICS, INC. (US) 2016-10-27 — — WO claimed
WO-2016085887-A1 TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES UCL BUSINESS PLC (GB) 2016-06-02 — — WO claimed
WO-2015114308-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY UMECRINE COGNITION AB (SE) 2015-08-06 — — WO claimed
CN-102421432-A L-ornithine phenylacetate and preparation method thereof OCERA THERAPEUTICS INC 2012-04-18 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170056416-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY CYP11B2, CYP11B1, HSD17B2 ALDH1A1 964/4885MAPK1 2446/4885L3MBTL1 4776/4885
US-20160338982-A1 FORMULATIONS OF L-ORNITHINE PHENYLACETATE OAT, OTC, ODC1 ALDH1A1 1120/4885MAPK1 2076/4885L3MBTL1 937/4885
US-20160339040-A1 STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY CYP11B2, CYP11B1, HSD17B2 ALDH1A1 964/4885MAPK1 2446/4885L3MBTL1 4776/4885
US-20250170157-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY OAT, GYS2, OTC ALDH1A1 1139/4885MAPK1 4558/4885L3MBTL1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.